Navigation Links
Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
Date:6/3/2011

QUEBEC CITY, June 3, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that Martin Driscoll has been appointed as chief executive officer.  With a solid foundation established at Asmacure, Mr. Driscoll will lead the company as it progresses its lead compound, a potential new treatment for asthma with a novel mechanism-of-action, further in clinical development.  Mr. Driscoll will be supported by the Asmacure team, including the company's founder and chief medical officer Dr. Yvon Cormier.  Dr. Luc Vachon, president and former CEO of Asmacure, will be departing the company to pursue other business ventures; however, he will remain actively involved with Mr. Driscoll and the company during a transitional period over the next few months.      

Mr. Driscoll has more than 30 years experience in the pharmaceutical industry, including senior roles in general management, commercial operations and business development for both privately held and publicly traded life science companies.  He led the commercialization of several successful therapeutic products, the direct negotiation of multiple transactions, licensing and M&A and the successful submission of multiple major product regulatory filings.  

Prior to being elected CEO of Asmacure, Mr. Driscoll was CEO and a director of Javelin Pharmaceuticals, Inc., a publicly traded company focused on the development of acute care pain products, from March 2008 until July 2010, at which point he led the successful merger of the company with Hospira, Inc.  Prior to his role with Javelin, Mr. Driscoll held senior managerial roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals.  During his tenure at Schering-Plough, Mr. Driscoll spent a significant amount of time as general manager of Key Pharmaceuticals, the Schering unit responsible for all respiratory products marketed in the U.S.        

"Given Mr. Driscoll's extensive experience, we are confident he will successfully lead Asmacure during this exciting period as the company advances the clinical development of Asmacure's novel nicotinic receptor-based programs," said Dr. John T. Henderson, Chairman of the Board for Asmacure.  

"I'm delighted to have joined a unique development company with such novel proprietary technology that has the potential to meet significant unmet medical needs and enhance current clinical practice.  The science that has been developed by the team at Asmacure under the leadership of Drs. Vachon and Cormier is truly impressive.  I look forward to closely working with the talented Asmacure team as we lead the company through this exciting time of development and growth," said Mr. Driscoll.

Mr. Driscoll holds a B.Sc. in Communications from the University of Texas at Austin.  He has also been recently appointed as a member of the board of the Epilepsy Foundation of New Jersey and served on the Advisory Board for the American Lung Association.

About Asmacure Ltee

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases.  The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma.  ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication.  Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.  

Asmacure is a privately held company located in Quebec City, Canada.  The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec.  For more information visit www.asmacure.com

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com  


'/>"/>
SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
2. Omeros Appoints David A. Mann to its Board of Directors
3. RainDance Technologies Appoints Olex Vice President, System Development
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
6. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
7. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
8. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
9. UltraShape Appoints Assaf Eyal as President & CEO
10. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
11. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
Breaking Biology Technology:
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):